Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Update

Achilles Therapeutics plc (NASDAQ:ACHL) was the recipient of a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 159,300 shares, a decline of 25.1% from the October 15th total of 212,600 shares. Approximately 0.4% of the company’s shares are sold short. Based on an average daily trading volume, of 642,000 shares, the short-interest ratio is presently 0.2 days.

Hedge Funds Weigh In On Achilles Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ACHL. BML Capital Management LLC increased its position in Achilles Therapeutics by 555.8% during the 3rd quarter. BML Capital Management LLC now owns 4,100,002 shares of the company’s stock valued at $4,182,000 after buying an additional 3,474,828 shares in the last quarter. XTX Topco Ltd boosted its stake in Achilles Therapeutics by 239.4% in the 2nd quarter. XTX Topco Ltd now owns 51,660 shares of the company’s stock worth $42,000 after purchasing an additional 36,441 shares in the last quarter. Ikarian Capital LLC purchased a new stake in Achilles Therapeutics during the 1st quarter valued at about $1,804,000. StemPoint Capital LP bought a new stake in Achilles Therapeutics during the 1st quarter valued at about $1,732,000. Finally, Acadian Asset Management LLC purchased a new position in Achilles Therapeutics in the first quarter worth about $350,000. Institutional investors own 56.38% of the company’s stock.

Achilles Therapeutics Price Performance

Shares of ACHL opened at $1.05 on Friday. Achilles Therapeutics has a one year low of $0.63 and a one year high of $1.76. The company has a 50-day simple moving average of $0.96 and a two-hundred day simple moving average of $0.87. The firm has a market capitalization of $43.14 million, a PE ratio of -0.64 and a beta of 1.35.

Achilles Therapeutics (NASDAQ:ACHL) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.41). Analysts expect that Achilles Therapeutics will post -1.7 EPS for the current fiscal year.

About Achilles Therapeutics

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.